Stromal tenascin distribution as a prognostic marker in colorectal cancer
1997

Tenascin as a Prognostic Marker in Colorectal Cancer

Sample size: 169 publication Evidence: moderate

Author Information

Author(s): U Kressner, G Lindmark, B Tomasini-Johansson, R Bergstrom, B Gerdin, L Pahlman, B Glimelius

Primary Institution: University Hospital, University of Uppsala

Hypothesis

The study investigates the association between tenascin staining patterns and survival in colorectal cancer patients.

Conclusion

Diffuse stromal fibrillar staining of tenascin is associated with shorter survival in colorectal cancer patients compared to subglandular staining.

Supporting Evidence

  • 54% of tumors showed diffuse stromal fibrillar staining.
  • Patients with diffuse staining had a significantly shorter survival time.
  • Dukes' stage and age were independent prognostic factors.

Takeaway

This study found that a specific protein called tenascin can help predict how long patients with colorectal cancer might live after treatment.

Methodology

Immunohistochemical staining was performed on cryosections of colorectal adenocarcinomas to evaluate tenascin expression in relation to tumor stage, differentiation, and survival.

Limitations

The additional prognostic value of tenascin remains to be established in further analyses after adjusting for age and Dukes' stage.

Participant Demographics

72 men and 97 women, ages ranging from 40 to 92 years, with a median age of 71.

Statistical Information

P-Value

0.06

Confidence Interval

0.98-2.99

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication